Good laboratory practice is the central dogma of all laboratory research and investigation - it's your commitment to regulators - and poor laboratory controls are a common cause of 483 observations and preapproval inspection failures.
Kevin Robinson
Advertisement
Articles by Kevin Robinson
by Kevin Robinson For "me too" manufacturers, the growth opportunity is in Europe ? and in biogenerics.
by Kevin Robinson, BioPharm International As we approach the end of 2002, biotechnology companies continue to be the standard bearers for innovation in the pharmaceutical industry.
Advertisement
Latest Updated Articles
GLPs and the Importance of Standard Operating ProceduresPublished: August 1st 2003 | Updated:
- European Editor's Report ? An Industry Comes of Age
Published: November 15th 2002 | Updated:
- Market Views: A Rocky Road for Generics
Published: January 15th 2003 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
